Wall Street Analysts See an 113.73% Upside in Compass Therapeutics, Inc. (CMPX): Can the Stock Really Move This High?

Core Viewpoint - Compass Therapeutics, Inc. (CMPX) has shown a significant price increase of 20.2% over the past four weeks, with a mean price target of $13.23 indicating an upside potential of 113.7% from the current trading price of $6.19 [1] Price Targets and Estimates - The mean estimate consists of 13 short-term price targets with a standard deviation of $6.47, where the lowest estimate of $8.00 suggests a 29.2% increase, while the highest estimate predicts a surge of 384.7% to $30.00 [2] - A low standard deviation indicates a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Analyst Sentiment and Earnings Estimates - Analysts have shown growing optimism regarding CMPX's earnings prospects, as evidenced by a positive trend in earnings estimate revisions, which correlates strongly with near-term stock price movements [11] - The Zacks Consensus Estimate for the current year has increased by 5.1% over the past month, with two estimates rising and no negative revisions [12] - CMPX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading, and reliance solely on them may not yield favorable returns [3][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]